J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026

Key Takeaways J&J advanced its pipeline in 2025 with key approvals across oncology and immunologyJNJ secured approvals for Inlexzoh, Imaavy and Icotyde, expanding treatment options and pipeline depthJNJ's new cancer drugs generated $3B in 2025, with more growth expected from launches in 2026Johnson & Johnson (JNJ) has a strong R&D pipeline, with primary focus areas being immunology, oncology and neuroscience. J&J rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones ...